[go: up one dir, main page]

PE70398A1 - Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa - Google Patents

Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa

Info

Publication number
PE70398A1
PE70398A1 PE1997000433A PE00043397A PE70398A1 PE 70398 A1 PE70398 A1 PE 70398A1 PE 1997000433 A PE1997000433 A PE 1997000433A PE 00043397 A PE00043397 A PE 00043397A PE 70398 A1 PE70398 A1 PE 70398A1
Authority
PE
Peru
Prior art keywords
formula
compounds
alkyl
substituted
salts
Prior art date
Application number
PE1997000433A
Other languages
English (en)
Inventor
Silvio Roggo
Kaspar Zimmermann
Claudia Betschart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE70398A1 publication Critical patent/PE70398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: ALK DE PREFERENCIA ES ALQUILIDENO INFERIOR; R ES UN GRUPO AMINO INSUSTITUIDO O SUSTITUIDO, POR ALQUILO C1-C4, POR FENILALQUILO C1-C4 (EN DONDE LA PARTE ALQUILICA ESTA SUSTITUIDA POR CARBOXI EVENTUALMENTE ESTERIFICADO), POR FENILALQUILENO C1-C4 O POR FENILALQUILO C1-C4-ALQUILENO C1-C4, ENTRE OTROS; R1, R2, R3 Y R4 SON H, ALQUILO C1-C4, ALCOXI C1-C4, HALOGENO, CF3. TAMBIEN SE REFIEREN A LAS SALES DE ADICION DE LOS COMPUESTOS DE FORMULA (I) Y AL PROCEDIMIENTO DE PREPARACION DE DICHA SAL, QUE COMPRENDE HACER REACCIONAR EL COMPUESTO DE FORMULA (I) EN FORMA LIBRE CON UN ACIDO ORGANICO TAL COMO EL ACIDO OXALICO, FUMARICO, MALEICO, SUCCINICO, DIMALEICO O DIFUMARICO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) Y SUS SALES DE ADICION SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS ESPECIALMENTE AQUELLAS RELACIONADAS A LA MUERTE CELULAR APOPTOTICA, TAL COMO ISQUEMIA CEREBRAL, LAS ENFERMEDADES DE ALZHEIMER, HUNTINGTON Y PARKINSON, LA ESCLEROSIS MULTIPLE Y LAS DIVERSAS CLASES DE GLAUCOMA, ASI COMO TAMBIEN EN EL TRATAMIENTO DE NEUROPATIAS PERIFERICAS GENERALES O DIABETICAS
PE1997000433A 1996-05-30 1997-05-28 Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa PE70398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH135296 1996-05-30

Publications (1)

Publication Number Publication Date
PE70398A1 true PE70398A1 (es) 1998-11-09

Family

ID=4208469

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000433A PE70398A1 (es) 1996-05-30 1997-05-28 Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa

Country Status (10)

Country Link
AR (1) AR008371A1 (es)
AU (1) AU3030397A (es)
CO (1) CO5080765A1 (es)
CZ (1) CZ296134B6 (es)
ID (1) ID18178A (es)
PE (1) PE70398A1 (es)
PL (1) PL191728B1 (es)
TR (1) TR199802482T2 (es)
WO (1) WO1997045422A1 (es)
ZA (1) ZA974802B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
WO2003057204A2 (en) * 2002-01-08 2003-07-17 Nordic Bioscience A/S Modulation of iamt (pimt or pcmt) in immune system
EP1589963A1 (en) * 2003-01-29 2005-11-02 Novartis AG Use of 10-aminoaliphatyl-dibenz b,f oxepines for the tr eatment of degenerative ocular disorders
PE20050487A1 (es) * 2003-11-06 2005-10-07 Novartis Ag Composiciones farmaceuticas estabilizadas
EA012610B1 (ru) 2004-09-21 2009-10-30 Хипнион, Инк. Аналоги локсапина и фармацевтические композиции на их основе
WO2006049734A2 (en) 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
EP1757284A1 (en) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
WO2014120885A1 (en) 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
DE1493782B1 (de) * 1964-06-29 1969-12-11 Geigy Ag J R Basisch substituierte Dibenzo[b,f]-oxepine und deren nicht-toxische Salze
CH585745A5 (es) * 1973-06-08 1977-03-15 Hoffmann La Roche
TW420672B (en) * 1995-02-08 2001-02-01 Novartis Ag Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz[b,f]oxepines

Also Published As

Publication number Publication date
WO1997045422A1 (en) 1997-12-04
CZ387898A3 (cs) 1999-02-17
AU3030397A (en) 1998-01-05
AR008371A1 (es) 2000-01-19
CZ296134B6 (cs) 2006-01-11
ZA974802B (en) 1998-11-30
TR199802482T2 (xx) 1999-02-22
PL191728B1 (pl) 2006-06-30
CO5080765A1 (es) 2001-09-25
PL330238A1 (en) 1999-05-10
ID18178A (id) 1998-03-12

Similar Documents

Publication Publication Date Title
Sartori et al. Bis-vinyl selenides obtained via iron (III) catalyzed addition of PhSeSePh to alkynes: Synthesis and antinociceptive activity
PE70398A1 (es) Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
KR870001151A (ko) 지질분해 활성을 갖는 신규 페닐에탄올 아미노테트랄린의 제조방법
AR003472A1 (es) Un procedimiento para preparar un alcohol terciario, un compuesto derivado de alfa-halo-alquil pirimidina y un compuesto intermediario para preparar 6-(1-bromoetil)-4-cloro-5-fluoropirimidina
AR241591A1 (es) Procedimiento pra la preparacion de nuevos derivados de piperazina con actividad antianafilactica y broncoespasmolitica.
PE20000055A1 (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos
DK0599890T3 (da) Geneserinderivater som cholinesteraseinhibitorer
PT96030A (pt) Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem
ES2038202T3 (es) Derivados de alcanos trifluorometil insecticidos.
KR850008666A (ko) 치환된 비스-(4-아미노페닐)-설폰의 제조방법
BR8601946A (pt) Composto regulador de crescimento de plantas,processo para sua preparacao,composicao reguladora de crescimento de plantas e processo para regular o crescimento de plantas
PT93535A (pt) Processo para preparacao de derivados da eserolina e de composicoes farmaceuticas que os contem
PE20241633A1 (es) Inhibidores de protoporfirinogeno oxidasa
PE20030517A1 (es) Composicion fungicida a base de al menos un derivado de piridil-metil-benzamida y de al menos un derivado ditio-carbamato
ES8306742A1 (es) "un procedimiento para la preparacion de 4-(4-imidazolil)-piridinas 2-sustituidas".
ATE22685T1 (de) Substituierte 1,3-diazolyl-2-propanole, verfahren zu ihrer herstellung und ihre verwendung als antimykotische mittel.
AR005226A1 (es) Herbicidas de 3-fenil-pirazol sustituidos
HUP9701364A2 (hu) Eljárás {1-metil-2-[3-(trifluor-metil)-fenil]-etil}-amin (R)- és (S)-izomereinek előállítására, és az izomerek és sóik
ES2038708T3 (es) Metodo para producir compuestos de benzotiepino(5,4-c)piridazina.
SE0104333D0 (sv) Therapeutic agents
PT89064A (pt) Processo para a preparacao de compostos piperidinil-1,4-dissubstituidos com accao analgesica e miorrelaxante
PT92189A (pt) Processo para a preparacao de derivados de difenilacetamidas e de composicoes farmaceuticas que os contem
AR247197A1 (es) Procedimiento para preparacion de nuevos compuestos broncoespasmoliticos
KR890701584A (ko) 20, 21-디노르에비나메닌의 신규 치환 유도체, 그의 제조 방법 및 이 방법으로 얻는 신규 중간체, 약제로서의 그의 용도 및 그를 함유하는 제약 조성물

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term